ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Evaluating Pneumococcal Meningitis in the Paediatric Population in Spain Four Years After the Marketing of Prevenar.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00227214
Recruitment Status : Completed
First Posted : September 27, 2005
Last Update Posted : June 28, 2010
Sponsor:
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary:
The aim of this study is to determine the prevalence of pneumococcal meningitis in the paediatric population in Spain four years after the marketing of Prevenar. Also secondary objectives are: 1) to determine the clinical characteristics and outcome of the disease; and 2) to determine serotypes and antibiotic resistance patterns.

Condition or disease
Pneumococcal Meningitis

Study Type : Observational
Actual Enrollment : 160 participants
Time Perspective: Prospective
Official Title: Prevalence of Pneumococcal Meningitis in the Paediatric Population in Spain Four Years After the Marketing of Prevenar.
Study Start Date : January 2004
Actual Primary Completion Date : December 2006
Actual Study Completion Date : December 2006






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 14 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Children from 0 up to 14 years of age with a diagnosis of confirmed or probable pneumococcal meningitis or with a diagnosis of suspected bacterial meningitis without bacterial or viral isolation.
Criteria

Inclusion Criteria:

  • All children from 0 up to 14 years with diagnosis of confirmed or probable pneumococcal meningitis or with diagnosis of suspected bacterial meningitis without bacterial or viral isolation will be included into the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00227214


Locations
Spain
Alcalá de Henares, Spain
Alcorcón, Spain
Badalona, Spain
Barakaldo, Spain
Barcelona, Spain
Barco de Valdeorras, Spain
Bilbao, Spain
Boadilla del Monte, Spain
CEE, Spain
Esplugues de Llobregat, Spain
Estella, Spain
Ferrol, Spain
Figueres, Spain
Getafe, Spain
Girona, Spain
Granollers, Spain
La Coruña, Spain
Leganés, Spain
Lleida, Spain
Lugo, Spain
Madrid, Spain
Mondragón, Spain
Monforte de Lemos, Spain
Móstoles, Spain
Ourense, Spain
Pamplona, Spain
Pontevedra, Spain
Reus, Spain
Ribeira, Spain
Sabadell, Spain
San Lorenzo de El Escorial, Spain
San Sebastián, Spain
Tarragona, Spain
Terrasa, Spain
Tudela, Spain
Verín, Spain
Vigo, Spain
Vitoria, Spain
Zumárraga, Spain
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Wyeth is now a wholly owned subsidiary of Pfizer

ClinicalTrials.gov Identifier: NCT00227214     History of Changes
Other Study ID Numbers: 0887X-101539
First Posted: September 27, 2005    Key Record Dates
Last Update Posted: June 28, 2010
Last Verified: June 2010

Additional relevant MeSH terms:
Meningitis
Meningitis, Pneumococcal
Central Nervous System Diseases
Nervous System Diseases
Meningitis, Bacterial
Central Nervous System Bacterial Infections
Bacterial Infections
Pneumococcal Infections
Streptococcal Infections
Gram-Positive Bacterial Infections
Central Nervous System Infections
Heptavalent Pneumococcal Conjugate Vaccine
Immunologic Factors
Physiological Effects of Drugs